NCT05644041
Intravesical Gem/Doce in Patients With NMIBC
Active, Not Recruiting
PHASE2Ages 18+InterventionalTreatmentUniversity of ArizonaInvestigator-initiated
~31 participants
Updated 2026-07-13 on ClinicalTrials.gov
What's tested:gemcitabine + docetaxel
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Complete response rate (CR) for treatment with intravesical gemcitabine for patients with intermediate and high-risk NMIBC
Measured over Complete response rate will be measured at the 3-month visit
Conditions
NCT05644041
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
University of Arizona Cancer Center
Tucson, Arizonano site contact published
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Juan Chipollini, MD · PRINCIPAL_INVESTIGATOR · University of Arizona
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Complete response rate (CR) for treatment with intravesical gemcitabine for patients with intermediate and high-risk NMIBCComplete response rate will be measured at the 3-month visit
The primary outcome measure will be CR rate, defined as the percentage of patients with CR at the 3-month visit. An event will be defined as the earliest date of recurrence as determined using the date of cystoscopy, biopsy, or cytology, whichever occurs first.